ADMS News and Press, Adamas Pharmaceuticals Inc. From 02/25/21

Adamas Pharmaceuticals (ADMS) -7% premarket on pricing public offering of 12.5M common shares at $4.40/share, for gross proceeds of $55M.Underwriters' over-allotment is an additional 1.875M shares.Offering is expected to close on March 1. For further details see: Adamas Pharmaceuti...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock...

Adamas Pharmaceuticals (ADMS) announces that it has commenced an underwritten public offering.The company intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of shares.SVB Leerink and William Blair are acting as joint bookrunning man...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of...

Adamas Pharmaceuticals, Inc. (ADMS) Q4 2020 Earnings Conference Call February 23, 2021 4:30 PM ET Company Participants Peter Vozzo – Investor Relations Representative Neil McFarlane – Chief Executive Officer Vijay Shreedhar – Chief Commercial Officer Chris Prentiss ȁ...

Adamas Pharma (ADMS): Q4 GAAP EPS of -$0.64 misses by $0.14.Revenue of $21M (+28.4% Y/Y) beats by $0.35M.Press Release For further details see: Adamas Pharma EPS misses by $0.14, beats on revenue

Fourth Quarter 2020 total revenues of $21.0 million, a 29% increase over fourth quarter 2019 Full Year 2020 total revenues of $74.5 million, a 36% increase over 2019 Second indication received February 2021 for GOCOVRI as an adjunctive treatment to levodopa/carbidopa i...

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2020 financial results on Tuesday, February 23, 2021, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m...

Adamas Pharma shares surged ([[ADMS]] +32.3%) after its GOCOVRI treatment won expanded approval from the U.S. FDA to be used as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes ((the reemergence of stiffness, rigidity and...

- GOCOVRI is now the first and only medication approved to treat OFF and dyskinesia motor complications - - Adamas to host webcast conference call today at 4:30 pm ET/1:30 pm PT - Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and deli...